Literature DB >> 22330929

Efficacy of posaconazole in murine experimental sporotrichosis.

Fabiola Fernández-Silva1, Javier Capilla, Emilio Mayayo, Josep Guarro.   

Abstract

We developed a murine model of systemic sporotrichosis by using three strains of each of the two commonest species causing sporotrichosis, i.e., Sporothrix schenckii sensu stricto and Sporothrix brasiliensis, in order to evaluate the efficacy of posaconazole (PSC). The drug was administered at a dose of 2.5 or 5 mg/kg of body weight twice a day by gavage, and one group was treated with amphotericin B (AMB) as a control treatment. Posaconazole, especially at 5 mg/kg, showed good efficacy against all the strains tested, regardless of their MICs, as measured by prolonged survival, tissue burden reduction, and histopathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330929      PMCID: PMC3346655          DOI: 10.1128/AAC.05376-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Sporotrichosis.

Authors:  C A Kauffman
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Use of a mouse model to evaluate clinical and environmental isolates of Sporothrix spp. from the largest U.S. epidemic of sporotrichosis.

Authors:  D M Dixon; R A Duncan; N J Hurd
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex.

Authors:  Valentina Salas; F Javier Pastor; M M Rodríguez; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 4.  Disseminated Sporothix schenckii in a patient with AIDS.

Authors:  S Hardman; I Stephenson; D R Jenkins; M J Wiselka; E M Johnson
Journal:  J Infect       Date:  2005-10       Impact factor: 6.072

5.  Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing.

Authors:  Lidiane Meire Kohler; Júnia Soares Hamdan; Teresa Cristina Abreu Ferrari
Journal:  Diagn Microbiol Infect Dis       Date:  2007-05       Impact factor: 2.803

6.  Variants of Sporothrix schenckii with attenuated virulence for mice.

Authors:  Renata Ferretti de Lima; Guido Vidal Schäffer; Cintia de Moraes Borba
Journal:  Microbes Infect       Date:  2003-09       Impact factor: 2.700

7.  Efficacies of four antifungal agents in experimental murine sporotrichosis.

Authors:  V L Kan; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

8.  Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest.

Authors:  Rita Marimon; Josep Cano; Josepa Gené; Deanna A Sutton; Masako Kawasaki; Josep Guarro
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

Review 9.  Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection.

Authors:  J A al-Tawfiq; K K Wools
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

10.  Cutaneous and meningeal sporotrichosis in a HIV patient.

Authors:  Raquel Vilela; Guenael F Souza; Gláucia Fernandes Cota; Leonel Mendoza
Journal:  Rev Iberoam Micol       Date:  2007-06       Impact factor: 1.044

View more
  12 in total

1.  Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.

Authors:  A Espinel-Ingroff; D P B Abreu; R Almeida-Paes; R S N Brilhante; A Chakrabarti; A Chowdhary; F Hagen; S Córdoba; G M Gonzalez; N P Govender; J Guarro; E M Johnson; S E Kidd; S A Pereira; A M Rodrigues; S Rozental; M W Szeszs; R Ballesté Alaniz; A Bonifaz; L X Bonfietti; L P Borba-Santos; J Capilla; A L Colombo; M Dolande; M G Isla; M S C Melhem; A C Mesa-Arango; M M E Oliveira; M M Panizo; Z Pires de Camargo; R M Zancope-Oliveira; J F Meis; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

2.  Canine sporotrichosis: polyphasic taxonomy and antifungal susceptibility profiles of Sporothrix species in an endemic area in Brazil.

Authors:  Jéssica Sepulveda Boechat; Sandro Antonio Pereira; Ana Caroline de Sá Machado; Paula Gonçalves Viana; Rodrigo Almeida-Paes; Rosely Maria Zancopé-Oliveira; Isabella Dib Ferreira Gremião; Manoel Marques Evangelista de Oliveira
Journal:  Braz J Microbiol       Date:  2020-07-02       Impact factor: 2.476

3.  In Vitro and In Vivo Efficacy of Amphotericin B Combined with Posaconazole against Experimental Disseminated Sporotrichosis.

Authors:  Débora Nunes Mario; Josep Guarro; Janio Morais Santurio; Sydney Hartz Alves; Javier Capilla
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

Review 4.  Dimorphic fungal osteoarticular infections.

Authors:  B Rammaert; M N Gamaletsou; V Zeller; C Elie; R Prinapori; S J Taj-Aldeen; E Roilides; D P Kontoyiannis; B Brause; N V Sipsas; T J Walsh; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

5.  Molecular Diagnosis of Pathogenic Sporothrix Species.

Authors:  Anderson Messias Rodrigues; G Sybren de Hoog; Zoilo Pires de Camargo
Journal:  PLoS Negl Trop Dis       Date:  2015-12-01

6.  Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis.

Authors:  Anderson Messias Rodrigues; G Sybren de Hoog; Débora de Cássia Pires; Raimunda Sâmia Nogueira Brihante; José Júlio da Costa Sidrim; Marcos Fabio Gadelha; Arnaldo Lopes Colombo; Zoilo Pires de Camargo
Journal:  BMC Infect Dis       Date:  2014-04-23       Impact factor: 3.090

Review 7.  Sporotrichosis: an overview and therapeutic options.

Authors:  Vikram K Mahajan
Journal:  Dermatol Res Pract       Date:  2014-12-29

8.  Sporothrix schenckii sensu stricto and Sporothrix brasiliensis Are Differentially Recognized by Human Peripheral Blood Mononuclear Cells.

Authors:  José A Martínez-Álvarez; Luis A Pérez-García; Erika Mellado-Mojica; Mercedes G López; Iván Martínez-Duncker; Leila M Lópes-Bezerra; Héctor M Mora-Montes
Journal:  Front Microbiol       Date:  2017-05-10       Impact factor: 5.640

Review 9.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 10.  Cutaneous Disseminated and Extracutaneous Sporotrichosis: Current Status of a Complex Disease.

Authors:  Alexandro Bonifaz; Andrés Tirado-Sánchez
Journal:  J Fungi (Basel)       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.